APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease

Kidney International

Volumn 90, Issue 2, 2016, Pages 389-395

  Ma, Lijun ^a   Langefeld, Carl D ^a   Comeau, Mary E ^a   Bonomo, Jason A ^a   Rocco, Michael V ^a   Burkart, John M ^a   Divers, Jasmin ^a   Palmer, Nicholette D ^a   Hicks, Pamela J ^a   Bowden, Donald W ^a   Lea, Janice P ^b   Krisher, Jenna O ^c   Clay, Margo J ^c   Freedman, Barry I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Southeastern Kidney Council Inc/ESRD Network 6   (United States)

Author keywords

African Americans; APOL1; diabetes mellitus; end stage kidney disease; hemodialysis; survival

Indexed keywords

ADULT; AFRICAN AMERICAN; APOL1 GENE; ARTERIOVENOUS FISTULA; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CAUCASIAN; DIABETIC NEPHROPATHIES; GENETICS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS;

APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

AFRICAN AMERICANS; AGED; APOLIPOPROTEINS; DIABETIC NEPHROPATHIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84992512192     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.02.032     Document Type: Article

References (35)

1. 1 Clark, L.T., Ferdinand, K.C., Flack, J.M., et al. Coronary heart disease in African Americans. Heart Dis 3 (2001), 97–108.
2. 2 Young, B.A., Rudser, K., Kestenbaum, B., et al. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: the USRDS. Kidney Int 69 (2006), 1691–1698.
3. 3 Kalantar-Zadeh, K., Kovesdy, C.P., Derose, S.F., et al. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol 3 (2007), 493–506.
4. 4 Kovesdy, C.P., Quarles, L.D., Lott, E.H., et al. Survival advantage in black versus white men with CKD: effect of estimated GFR and case mix. Am J Kidney Dis 62 (2013), 228–235.
5. 5 Kovesdy, C.P., Norris, K.C., Boulware, L.E., et al. Association of race with mortality and cardiovascular events in a large cohort of US veterans. Circulation 132 (2015), 1538–1548.
6. 6 Kucirka, L.M., Grams, M.E., Lessler, J., et al. Association of race and age with survival among patients undergoing dialysis. JAMA 306 (2011), 620–626.
7. 7 Karter, A.J., Ferrara, A., Liu, J.Y., et al. Ethnic disparities in diabetic complications in an insured population. JAMA 287 (2002), 2519–2527.
8. 8 Young, B.A., Maynard, C., Boyko, E.J., Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 26 (2003), 2392–2399.
9. 9 Newman, A.B., Naydeck, B.L., Whittle, J., et al. Racial differences in coronary artery calcification in older adults. Arterioscler Thromb Vasc Biol 22 (2002), 424–430.
10. 10 Bild, D.E., Detrano, R., Peterson, D., et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 111 (2005), 1313–1320.
11. 11 Lee, T.C., O'Malley, P.G., Feuerstein, I., et al. The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects. J Am Coll Cardiol 41 (2003), 39–44.
12. 12 Freedman, B.I., Hsu, F.C., Langefeld, C.D., et al. The impact of ethnicity and sex on subclinical cardiovascular disease: the Diabetes Heart Study. Diabetologia 48 (2005), 2511–2518.
13. 13 Carnethon, M.R., Bertoni, A.G., Shea, S., et al. Racial/ethnic differences in subclinical atherosclerosis among adults with diabetes: the multiethnic study of atherosclerosis. Diabetes Care 28 (2005), 2768–2770.
14. 14 Wassel, C.L., Pankow, J.S., Peralta, C.A., et al. Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Genet 2 (2009), 629–636.
15. 15 Divers, J., Palmer, N.D., Lu, L., et al. Admixture mapping of coronary artery calcified plaque in African Americans with type 2 diabetes mellitus. Circ Cardiovasc Genet 6 (2013), 97–105.
16. 16 Genovese, G., Friedman, D.J., Ross, M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329 (2010), 841–845.
17. 17 Tzur, S., Rosset, S., Shemer, R., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128 (2010), 345–350.
18. 18 Freedman, B.I., Kopp, J.B., Langefeld, C.D., et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21 (2010), 1422–1426.
19. 19 Lipkowitz, M.S., Apolipoprotein L1: from obscurity to consistency to controversy. Kidney Int 87 (2015), 14–17.
20. 20 Ito, K., Bick, A.G., Flannick, J., et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 114 (2014), 845–850.
21. 21 Freedman, B.I., Langefeld, C.D., Lu, L., et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int 87 (2015), 176–181.
22. 22 Mukamal, K.J., Tremaglio, J., Friedman, D.J., et al. APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol 36 (2016), 398–403.
23. 23 Gonzalez Suarez, M.L., Thomas, D.B., Barisoni, L., et al. Diabetic nephropathy: is it time yet for routine kidney biopsy?. World J Diabetes 4 (2013), 245–255.
24. 24 Kruzel-Davila, E., Wasser, W.G., Aviram, S., et al. APOL1 nephropathy: from gene to mechanisms of kidney injury. Nephrol Dial Transplant 31 (2016), 349–358.
25. 25 Freedman, B.I., Cohen, A.H., Hypertension-attributed nephropathy: what's in a name?. Nat Rev Nephrol 12 (2016), 27–36.
26. 26 Langefeld, C.D., Divers, J., Pajewski, N.M., et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int 87 (2015), 169–175.
27. 27 Skorecki, K.L., Wasser, W.G., Hypertension-misattributed kidney disease in African Americans. Kidney Int 83 (2013), 6–9.
28. 28 Parsa, A., Kao, W.H., Xie, D., et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369 (2013), 2183–2196.
29. 29 Appel, L.J., Wright, J.T. Jr., Greene, T., et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363 (2010), 918–929.
30. 30 Alves, T.P., Wang, X., Wright, J.T. Jr., et al. Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol 21 (2010), 1361–1369.
31. 31 Freedman, B.I., Soucie, J.M., Kenderes, B., et al. Family history of end-stage renal disease does not predict dialytic survival. Am J Kidney Dis 38 (2001), 547–552.
32. 32 Freedman, B.I., Langefeld, C.D., Lu, L., et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans. PLoS Genet, 7, 2011, e1002150.
33. 33 Iyengar, S.K., Sedor, J.R., Freedman, B.I., et al. Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: Family Investigation of Nephropathy and Diabetes (FIND). PLoS Genet, 11, 2015, e1005352.
34. 34 Zarif, L., Covic, A., Iyengar, S., et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant 15 (2000), 1801–1807.
35. 35 Freedman, B.I., Langefeld, C.D., Turner, J., et al. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease. Kidney Int 82 (2012), 805–811.